Zobrazeno 1 - 10
of 107
pro vyhledávání: ''
Autor:
Krystal Bergin, Andrew Spencer, Anna Kalff, Shreerang Sirdesai, John V. Reynolds, Craig T. Wallington-Beddoe, Flora Yuen
Publikováno v:
British Journal of Haematology. 194:580-586
We evaluated the efficacy and tolerability of continuous ixazomib-thalidomide-dexamethasone (ITd: 4 mg, day 1, 8, 15; 100 mg daily; and 40 mg weekly). A total of 39 patients with relapsed/refractory multiple myeloma (RRMM) aged ≥18 years with one t
Autor:
Neil Rabin, Charlotte Pawlyn, Priya Sriskandarajah, Susanna Nallamilli, Martin Kaiser, Kevin Boyd, Rakesh Popat, Kwee Yong, Sarah Bird
Publikováno v:
British Journal of Haematology. 191:927-930
Autor:
Loretta J. Nastoupil, Nada Hamad, John Casey, Chan Yoon Cheah, Andrew Grigg, Collin K. Chin, Peter Wood, Kate Manos, Eliza A Hawkes, Maher K. Gandhi, Katharine L Lewis, Shir Jing Ho, Bryan Do, Julie Crawford, Samar Issa
Publikováno v:
British Journal of Haematology. 192:1049-1053
Primary and secondary central nervous system lymphomas (PCNSL/SCNSL) are aggressive rare malignancies with dismal outcomes. Encouraging data have emerged from Phase I/II clinical trials treating relapsed/refractory PCNSL/SCNSL with ibrutinib. We anal
Autor:
Elena Guillen, Adriana García-Herrera, Sara Fernández, Esteban Poch, Josep M. Campistol, Alexandra Martínez-Roca, Joan Bladé, Miquel Blasco, Carlos Fernández de Larrea, María Teresa Cibeira, Luis F. Quintana, Marta Palomo, Natalia Tovar, Pedro Castro, Maribel Diaz-Ricart, Enric Carreras, Laura Rosiñol, Raquel Jiménez, Luis G. Rodríguez‐Lobato
Publikováno v:
British Journal of Haematology. 193:181-187
Carfilzomib has been associated with the development of thrombotic microangiopathy (TMA) in relapsed/refractory multiple myeloma patients, a severe disease with no currently available aetiological treatment. We evaluated the potential role of termina
Autor:
Nicola E. Potter, Manohursingh Runglall, Adam Ivey, Anthony P. Schwarer, Kavita Raj, Phillip C. Nguyen, Nigel H. Russell, Chun Yew Fong, Annie‐Louise Latif, Andrew H. Wei, Tse-Chieh Teh, Andrew Grigg, Nicholas James Cummings, Ing Soo Tiong, Richard Dillon, David Taussig
Publikováno v:
British Journal of Haematology
Summary Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1 mut measurable residual disease (MRD) using off‐label venetoclax in combination with low‐dose cytarabine or azacitidine. Twelve c
Autor:
Ashutosh D. Wechalekar, Carol J. Whelan, Charalampia Kyriakou, Ana Martinez-Naharro, Neil Rabin, Raakhee Shah, Sajitha Sachchithanantham, Shameem Mahmood, Julian D. Gillmore, Simon Cheesman, Faye Sharpley, Philip N. Hawkins, Kwee Yong, Oliver C Cohen, Helen J. Lachmann, Marianna Fontana, Rakesh Popat
Publikováno v:
British Journal of Haematology. 189:643-649
With improving outcomes in amyloid light-chain (AL) amyloidosis, there is a need to study novel agents in this setting. We report outcomes of 40 patients with relapsed AL amyloidosis treated with ixazomib + lenalidomide + dexamethasone (IRd). Haemato
Publikováno v:
British Journal of Haematology. 189:369-378
Current first-line treatments for immune thrombocytopenia (ITP) usually have transient effects and sustained platelet response off therapy remains low. We evaluated whether eltrombopag plus pulsed dexamethasone as first-line therapy can increase the
Autor:
Melody R. Becnel, Andrew M. Evens, Stephen D. Smith, Pooja Mehra, Amrita Desai, Prathima Reddy, Dhruvika Mukhija, Max L. Goldman, Bita Fakhri, James R. Cerhan, Brad S. Kahl, Abhigna Kodali, Jonathon B. Cohen, Brian K. Link, Juan Pablo Alderuccio, Deepa Jagadeesh, Nilanjan Ghosh, Allison M. Winter, Izidore S. Lossos, Thomas M. Habermann, Mohammad Junaid Hussain, Oscar Calzada, Timothy Tiutan, Peter Martin, Loretta J. Nastoupil, Craig A. Portell, Matthew J. Maurer, Brian T. Hill, Paolo Caimi
Publikováno v:
British journal of haematology, vol 184, iss 4
Bendamustine (B) with rituximab (R) is a standard frontline treatment for medically fit follicular lymphoma (FL) patients. The safety and efficacy of maintenance rituximab (MR) after BR induction has not been formally compared to observation for FL,
Autor:
Zhaoyang Teng, Andrew Spencer, Catriona Byrne, Wiesław Wiktor Jędrzejczak, Shaji Kumar, Marie-Christine Kyrtsonis, Norbert Grzasko, Meletios A. Dimopoulos, Richard Labotka, Neeraj Gupta, Sebastian Grosicki, Sosana Delimpasi
Publikováno v:
British Journal of Haematology. 184:536-546
There is a need for efficacious, convenient treatments with long-term tolerability for patients with relapsed/refractory multiple myeloma (RRMM). This phase 2 study evaluated the all-oral combination of ixazomib, cyclophosphamide and dexamethasone (I
Autor:
Oliver W. Press, Kiarash Kojouri, Mary Philip, David Wu, Andrei R. Shustov, Edward N. Libby, Jennifer E. Roden, Stephen D. Smith, Tara L. Chen, Daniel Martin, Ajay K. Gopal, Alan Langerak, Lihua E. Budde, Ted Gooley, Eric Y. Chen
Publikováno v:
British Journal of Haematology. 183:601-607
We sought to develop a safe and effective outpatient salvage regimen by replacing ifosfamide within the (R)ICE (rituximab, ifosfomide, carboplatin, etoposide) regimen with bendamustine (T(R)EC) via a multicentre phase I/II study for patients with rel